{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:05:57Z","timestamp":1793646357881,"version":"4.5.1"},"reference-count":90,"publisher":"Bentham Science Publishers Ltd.","issue":"37","license":[{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2020,11,6]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Osteoporosis is a skeletal pathology characterized by compromised bone strength leading\nto increased risk of fracture, mainly the spine and hip fractures. Osteoporosis affects more than 200\nmillion people worldwide and because of the skeletal fractures it causes, represents a major cause of\nmorbidity, disability and mortality in older people. Recently, the new discoveries of osteoimmunology\nhave clarified many of the pathogenetic mechanisms of osteoporosis, helping to identify new\nimmunological targets for its treatment opening the way for new and effective therapies with biological\ndrugs. Currently, there are basically two monoclonal antibodies for osteoporosis therapy:\ndenosumab and romosozumab. Here, we focus on the modern approach to the osteoporosis management\nand in particular, on current and developing biologic drugs targeted to new immunological\ncheckpoints, in the landscape of osteoimmunology.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867326666190730113123","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T04:36:07Z","timestamp":1564547767000},"page":"6356-6372","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Osteoporosis: Current and Emerging Therapies Targeted to Immunological Checkpoints"],"prefix":"10.2174","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4253-1312","authenticated-orcid":true,"given":"Massimo","family":"De Martinis","sequence":"first","affiliation":[{"name":"Department of Life, Health, & Environmental Sciences, University of L\u2019Aquila, L'Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1006-7121","authenticated-orcid":true,"given":"Maria Maddalena","family":"Sirufo","sequence":"additional","affiliation":[{"name":"Department of Life, Health, & Environmental Sciences, University of L\u2019Aquila, L'Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1841-2807","authenticated-orcid":true,"given":"Lia","family":"Ginaldi","sequence":"additional","affiliation":[{"name":"Department of Life, Health, & Environmental Sciences, University of L\u2019Aquila, L'Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.7326\/AITC201708010","volume":"167","author":"Ensrud K.E.","year":"2017","unstructured":"Ensrud K.E.; Crandall C.; J. Osteoporosis. Ann Intern Med 2017,167(3),17-32","journal-title":"Ann Intern Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1055\/s-0038-1660790","volume":"6","author":"Akkawi I.","year":"2018","unstructured":"Akkawi I.; Zmerly H.; Osteoporosis: Current Concepts. Joints 2018,6(2),122-127","journal-title":"Joints"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11739-018-1874-2","volume":"14","author":"Nuti R.","year":"2019","unstructured":"Nuti R.; Brandi M.L.; Checchia G.; Di Munno O.; Dominguez L.; Falaschi P.; Fiore C.E.; Iolascon G.; Maggi S.; Michieli R.; Migliaccio S.; Minisola S.; Rossini M.; Sessa G.; Tarantino U.; Toselli A.; Isaia G.C.; Guidelines for the management of osteoporosis and fragility fractures. Intern Emerg Med 2019,14(1),85-102","journal-title":"Intern Emerg Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"Hernlund E.","year":"2013","unstructured":"Hernlund E.; Svedbom A.; Iverg\u00e5rd M.; Compston J.; Cooper C.; Stenmark J.; McCloskey E.V.; J\u00f6nsson B.; Kanis J.A.; Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2013,8,136","journal-title":"Arch Osteoporos"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00011-006-6034-x","volume":"55","author":"De Martinis M.","year":"2006","unstructured":"De Martinis M.; Di Benedetto M.C.; Mengoli L.P.; Ginaldi L.; Senile osteoporosis: is it an immune-mediated disease? Inflamm Res 2006,55(10),399-404","journal-title":"Inflamm Res"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00223-017-0322-z","volume":"102","author":"Bultink I.E.M.","year":"2018","unstructured":"Bultink I.E.M.; Bone disease in connective tissue disease\/systemic lupus erythematosus. Calcif Tissue Int 2018,102(5),575-591","journal-title":"Calcif Tissue Int"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1586\/1744666X.2016.1125782","volume":"12","author":"De Martinis M.","year":"2016","unstructured":"De Martinis M.; Ciccarelli F.; Sirufo M.M.; Ginaldi L.; An overview of environmental risk factors in systemic sclerosis. Expert Rev Clin Immunol 2016,12(4),465-478","journal-title":"Expert Rev Clin Immunol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/1759720X14546350","volume":"6","author":"Panday K.","year":"2014","unstructured":"Panday K.; Gona A.; Humphrey M.B.; Medication-induced osteoporosis: screening and treatment strategies. Ther Adv Musculoskelet Dis 2014,6(5),185-202","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41574-018-0059-4","volume":"14","author":"Franceschi C.","year":"2018","unstructured":"Franceschi C.; Garagnani P.; Parini P.; Giuliani C.; Santoro A.; Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol 2018,14(10),576-590","journal-title":"Nat Rev Endocrinol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1152\/physrev.00036.2016","volume":"97","author":"Okamoto K.","year":"2017","unstructured":"Okamoto K.; Nakashima T.; Shinohara M.; Negishi-Koga T.; Komatsu N.; Terashima A.; Sawa S.; Nitta T.; Takayanagi H.; Osteoimmunology: the conceptual framework unifying the immune and skeletal systems. Physiol Rev 2017,97(4),1295-1349","journal-title":"Physiol Rev"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.2174\/0929867323666160907162546","volume":"23","author":"Ginaldi L.","year":"2016","unstructured":"Ginaldi L.; De Martinis M.; Osteoimmunology and beyond. Curr Med Chem 2016,23(33),3754-3774","journal-title":"Curr Med Chem"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00198-016-3894-y","volume":"28","author":"Harvey N.C.W.","year":"2017","unstructured":"Harvey N.C.W.; McCloskey E.V.; Mitchell P.J.; Dawson-Hughes B.; Pierroz D.D.; Reginster J.Y.; Rizzoli R.; Cooper C.; Kanis J.A.; Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int 2017,28(5),1507-1529","journal-title":"Osteoporos Int"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1001\/jama.2017.21995","volume":"319","author":"Cotts K.G.","year":"2018","unstructured":"Cotts K.G.; Cifu A.S.; Treatment of osteoporosis. JAMA 2018,319(10),1040-1041","journal-title":"JAMA"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00198-011-1796-6","volume":"23","author":"Kanis J.A.","year":"2012","unstructured":"Kanis J.A.; Reginster J.Y.; Kaufman J.M.; Ringe J.D.; Adachi J.D.; Hiligsmann M.; Rizzoli R.; Cooper C.; A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int 2012,23(1),213-221","journal-title":"Osteoporos Int"},{"key":"ref=15","first-page":"1437","volume":"9","author":"Martinkovich S.","year":"2014","unstructured":"Martinkovich S.; Shah D.; Planey S.L.; Arnott J.A.; Selective estrogen receptor modulators: tissue specificity and clinical utility. Clin Interv Aging 2014,9,1437-1452","journal-title":"Clin Interv Aging"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11914-017-0353-4","volume":"15","author":"Leder B.Z.","year":"2017","unstructured":"Leder B.Z.; Parathyroid hormone and parathyroid hormone-related protein analogs in osteoporosis therapy. Curr Osteoporos Rep 2017,15(2),110-119","journal-title":"Curr Osteoporos Rep"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/1759720X09343221","volume":"1","author":"Lewiecki E.M.","year":"2009","unstructured":"Lewiecki E.M.; Denosumab in postmenopausal osteoporosis: what the clinician needs to know. Ther Adv Musculoskelet Dis 2009,1(1),13-26","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1177\/0004563218759371","volume":"55","author":"Kenkre J.S.","year":"2018","unstructured":"Kenkre J.S.; Bassett J.; The bone remodelling cycle. Ann Clin Biochem 2018,55(3),308-327","journal-title":"Ann Clin Biochem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nrrheum.2014.219","volume":"11","author":"Takayanagi H.","year":"2015","unstructured":"Takayanagi H.; Osteoimmunology in 2014: Two-faced immunology-from osteogenesis to bone resorption. Nat Rev Rheumatol 2015,11(2),74-76","journal-title":"Nat Rev Rheumatol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3389\/fimmu.2018.00657","volume":"9","author":"Srivastava R.K.","year":"2018","unstructured":"Srivastava R.K.; Dar H.Y.; Mishra P.K.; Immunoporosis: immunology of osteoporosis-role of T cells. Front Immunol 2018,9,657","journal-title":"Front Immunol"},{"key":"ref=21","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28207","author":"Amjadi-Moheb F.","year":"2019","unstructured":"Amjadi-Moheb F.; Akhavan-Niaki H.; Wnt signaling pathway in osteoporosis: Epigenetic regulation, interaction with other signaling pathways, and therapeutic promises. J Cell Physiol 2019","journal-title":"J Cell Physiol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1007\/s00018-018-2881-1","volume":"75","author":"Uehara S.","year":"2018","unstructured":"Uehara S.; Udagawa N.; Kobayashi Y.; Non-canonical Wnt signals regulate cytoskeletal remodeling in osteoclasts. Cell Mol Life Sci 2018,75(20),3683-3692","journal-title":"Cell Mol Life Sci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"98673","DOI":"10.1172\/jci.insight.98673","volume":"3","author":"Witcher P.C.","year":"2018","unstructured":"Witcher P.C.; Miner S.E.; Horan D.J.; Bullock W.A.; Lim K.E.; Kang K.S.; Adaniya A.L.; Ross R.D.; Loots G.G.; Robling A.G.; Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition. JCI Insight 2018,3(11),98673","journal-title":"JCI Insight"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","volume":"96","author":"Delgado-Calle J.","year":"2017","unstructured":"Delgado-Calle J.; Sato A.Y.; Bellido T.; Role and mechanism of action of sclerostin in bone. Bone 2017,96,29-37","journal-title":"Bone"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/jbmr.3702","volume":"34","author":"Colditz J.","year":"2019","unstructured":"Colditz J.; Thiele S.; Baschant U.; Garbe A.I.; Niehrs C.; Hofbauer L.C.; Rauner M.; Osteogenic Dkk1 mediates glucocorticoid-induced but not arthritis-induced bone loss. J Bone Miner Res 2019,34(7),1314-1323","journal-title":"J Bone Miner Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2174\/0929867321666141106125051","volume":"22","author":"Ciccarelli F.","year":"2015","unstructured":"Ciccarelli F.; De Martinis M.; Ginaldi L.; Glucocorticoids in patients with rheumatic diseases: friends or enemies of bone? Curr Med Chem 2015,22(5),596-603","journal-title":"Curr Med Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3109\/09513590.2014.975683","volume":"31","author":"Zhang J.","year":"2015","unstructured":"Zhang J.; Fu Q.; Ren Z.; Wang Y.; Wang C.; Shen T.; Wang G.; Wu L.; Changes of serum cytokines-related Th1\/Th2\/Th17 concentration in patients with postmenopausal osteoporosis. Gynecol Endocrinol 2015,31(3),183-190","journal-title":"Gynecol Endocrinol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2147\/TCRM.S156350","volume":"14","author":"Suzuki T.","year":"2018","unstructured":"Suzuki T.; Nakamura Y.; Kato H.; Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis. Ther Clin Risk Manag 2018,14,453-459","journal-title":"Ther Clin Risk Manag"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00198-019-04874-2","volume":"30","author":"Saribal D.","year":"2019","unstructured":"Saribal D.; Hocaoglu-Emre F.S.; Erdogan S.; Bahtiyar N.; Caglar Okur S.; Mert M.; Inflammatory cytokines IL-6 and TNF-\u03b1 in patients with hip fracture. Osteoporos Int 2019,30(5),1025-1031","journal-title":"Osteoporos Int"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12865-015-0125-9","volume":"16","author":"Ginaldi L.","year":"2015","unstructured":"Ginaldi L.; De Martinis M.; Ciccarelli F.; Saitta S.; Imbesi S.; Mannucci C.; Gangemi S.; Increased levels of interleukin 31 (IL-31) in osteoporosis. BMC Immunol 2015,16,60","journal-title":"BMC Immunol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jaci.2019.02.028","volume":"144","author":"Holgado A.","year":"2019","unstructured":"Holgado A.; Braun H.; Van Nuffel E.; Detry S.; Schuijs M.J.; Deswarte K.; Vergote K.; Haegman M.; Baudelet G.; Haustraete J.; Hammad H.; Lambrecht B.N.; Savvides S.N.; Afonina I.S.; Beyaert R.; IL-33trap is a novel IL-33-neutralizing biologic that inhibits allergic airway inflammation. J Allergy Clin Immunol 2019,144(1),204-215","journal-title":"J Allergy Clin Immunol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1038\/s41598-019-40212-6","volume":"9","author":"Ginaldi L.","year":"2019","unstructured":"Ginaldi L.; De Martinis M.; Saitta S.; Sirufo M.M.; Mannucci C.; Casciaro M.; Ciccarelli F.; Gangemi S.; Interleukin-33 serum levels in postmenopausal women with osteoporosis. Sci Rep 2019,9(1),3786","journal-title":"Sci Rep"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"162","DOI":"10.14336\/AD.2016.0831","volume":"8","author":"De Martinis M.","year":"2017","unstructured":"De Martinis M.; Sirufo M.M.; Ginaldi L.; Allergy and aging: an old\/new emerging health issue. Aging Dis 2017,8(2),162-175","journal-title":"Aging Dis"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"464","DOI":"10.2741\/4600","volume":"23","author":"Dar H.Y.","year":"2018","unstructured":"Dar H.Y.; Azam Z.; Anupam R.; Mondal R.K.; Srivastava R.K.; Osteoimmunology: the Nexus between bone and immune system. Front Biosci 2018,23,464-492","journal-title":"Front Biosci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.critrevonc.2018.10.011","volume":"133","author":"van Dam P.A.","year":"2019","unstructured":"van Dam P.A.; Verhoeven Y.; Trinh X.B.; Wouters A.; Lardon F.; Prenen H.; Smits E.; Baldewijns M.; Lammens M.; RANK\/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment. Crit Rev Oncol Hematol 2019,133,85-91","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1177\/0300985816681409","volume":"54","author":"Massimini M.","year":"2017","unstructured":"Massimini M.; Palmieri C.; De Maria R.; Romanucci M.; Malatesta D.; De Martinis M.; Maniscalco L.; Ciccarelli A.; Ginaldi L.; Buracco P.; Bongiovanni L.; Della Salda L.; 17-AAG and apoptosis, autophagy, and mitophagy in canine osteosarcoma cell lines. Vet Pathol 2017,54(3),405-412","journal-title":"Vet Pathol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13046-018-1001-2","volume":"38","author":"Infante M.","year":"2019","unstructured":"Infante M.; Fabi A.; Cognetti F.; Gorini S.; Caprio M.; Fabbri A.; RANKL\/RANK\/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. J Exp Clin Cancer Res 2019,38(1),12","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.3390\/cancers10060182","volume":"10","author":"Shupp A.B.","year":"2018","unstructured":"Shupp A.B.; Kolb A.D.; Mukhopadhyay D.; Bussard K.M.; Cancer metastases to bone: concepts, mechanisms, and interactions with bone osteoblasts. Cancers (Basel) 2018,10,3390","journal-title":"Cancers (Basel)"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.ijbiomac.2017.03.021","volume":"99","author":"Vishal M.","year":"2017","unstructured":"Vishal M.; Swetha R.; Thejaswini G.; Arumugam B.; Selvamurugan N.; Role of Runx2 in breast cancer-mediated bone metastasis. Int J Biol Macromol 2017,99,608-614","journal-title":"Int J Biol Macromol"},{"key":"ref=40","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.160230","volume":"6","author":"Sigl V.","year":"2016","unstructured":"Sigl V.; Jones L.P.; Penninger J.M.; RANKL\/RANK: from bone loss to the prevention of breast cancer. Open Biol 2016,6(11)","journal-title":"Open Biol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"Baron R.","year":"2011","unstructured":"Baron R.; Ferrari S.; Russell R.G.; Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2011,48(4),677-692","journal-title":"Bone"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"Bone H.G.","year":"2017","unstructured":"Bone H.G.; Wagman R.B.; Brandi M.L.; Brown J.P.; Chapurlat R.; Cummings S.R.; Czerwi\u0144ski E.; Fahrleitner-Pammer A.; Kendler D.L.; Lippuner K.; Reginster J.Y.; Roux C.; Malouf J.; Bradley M.N.; Daizadeh N.S.; Wang A.; Dakin P.; Pannacciulli N.; Dempster D.W.; Papapoulos S.; 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 2017,5(7),513-523","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"Cummings S.R.","year":"2009","unstructured":"Cummings S.R.; San Martin J.; McClung M.R.; Siris E.S.; Eastell R.; Reid I.R.; Delmas P.; Zoog H.B.; Austin M.; Wang A.; Kutilek S.; Adami S.; Zanchetta J.; Libanati C.; Siddhanti S.; Christiansen C.; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009,361(8),756-765","journal-title":"N Engl J Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/joim.12873","volume":"285","author":"Lorentzon M.","year":"2019","unstructured":"Lorentzon M.; Treating osteoporosis to prevent fractures: current concepts and future developments. J Intern Med 2019,285(4),381-394","journal-title":"J Intern Med"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","volume":"29","author":"Zanchetta M.B.","year":"2018","unstructured":"Zanchetta M.B.; Boailchuk J.; Massari F.; Silveira F.; Bogado C.; Zanchetta J.R.; Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study. Osteoporos Int 2018,29(1),41-47","journal-title":"Osteoporos Int"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jocd.2016.01.004","volume":"19","author":"Leder B.Z.","year":"2016","unstructured":"Leder B.Z.; Tsai J.N.; Neer R.M.; Uihlein A.V.; Wallace P.M.; Burnett-Bowie S.A.; Response to therapy with teriparatide, denosumab, or both in postmenopausal women in the DATA (denosumab and teriparatide administration) study randomized controlled trial. J Clin Densitom 2016,19(3),346-351","journal-title":"J Clin Densitom"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bone.2017.03.006","volume":"98","author":"Leder B.Z.","year":"2017","unstructured":"Leder B.Z.; Tsai J.N.; Jiang L.A.; Lee H.; Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up). Bone 2017,98,54-58","journal-title":"Bone"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/jbm4.10041","volume":"2","author":"Leder B.Z.","year":"2018","unstructured":"Leder B.Z.; Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy. JBMR Plus 2018,2(2),62-68","journal-title":"JBMR Plus"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1080\/14740338.2016.1177021","volume":"15","author":"Fusco V.","year":"2016","unstructured":"Fusco V.; Santini D.; Armento G.; Tonini G.; Campisi G.; Osteonecrosis of jaw beyond antiresorptive (bone targeted) agents: new horizons in oncology. Expert Opin Drug Saf 2016,15(7),925-935","journal-title":"Expert Opin Drug Saf"},{"key":"ref=50","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000014701","volume":"98","author":"Suh Y.S.","year":"2019","unstructured":"Suh Y.S.; Jang B.W.; Nho J.H.; Won S.H.; Lee W.S.; Atypical incomplete femoral neck fracture in patients taking long-term bisphosphonate: Case report, a report of 2 cases. Medicine (Baltimore) 2019,98(9)","journal-title":"Medicine (Baltimore)"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00198-018-4790-4","volume":"30","author":"Lou S.","year":"2019","unstructured":"Lou S.; Lv H.; Yin P.; Li Z.; Tang P.; Wang Y.; Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int 2019,30(1),59-70","journal-title":"Osteoporos Int"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejphar.2018.02.028","volume":"826","author":"Bhattacharyya S.","year":"2018","unstructured":"Bhattacharyya S.; Pal S.; Chattopadhyay N.; Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: A critical assessment of the mechanism of action. Eur J Pharmacol 2018,826,39-47","journal-title":"Eur J Pharmacol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"8758","DOI":"10.12659\/MSM.912309","volume":"24","author":"Chang B.","year":"2018","unstructured":"Chang B.; Quan Q.; Li Y.; Qiu H.; Peng J.; Gu Y.; Treatment of osteoporosis, with a focus on 2 monoclonal antibodies. Med Sci Monit 2018,24,8758-8766","journal-title":"Med Sci Monit"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.maturitas.2014.04.016","volume":"78","author":"Clarke B.L.","year":"2014","unstructured":"Clarke B.L.; Anti-sclerostin antibodies: utility in treatment of osteoporosis. Maturitas 2014,78(3),199-204","journal-title":"Maturitas"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1002\/jbmr.474","volume":"26","author":"van Lierop A.H.","year":"2011","unstructured":"van Lierop A.H.; Hamdy N.A.; Hamersma H.; van Bezooijen R.L.; Power J.; Loveridge N.; Papapoulos S.E.; Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res 2011,26(12),2804-2811","journal-title":"J Bone Miner Res"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bone.2017.01.019","volume":"96","author":"Robling A.G.","year":"2017","unstructured":"Robling A.G.; Drake M.T.; Papapoulos S.E.; Sclerostin: From bedside to bench, and back to bedside. Bone 2017,96,1-2","journal-title":"Bone"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jbmr.3622","volume":"34","author":"Lewiecki E.M.","year":"2019","unstructured":"Lewiecki E.M.; Dinavahi R.V.; Lazaretti-Castro M.; Ebeling P.R.; Adachi J.D.; Miyauchi A.; Gielen E.; Milmont C.E.; Libanati C.; Grauer A.; One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Miner Res 2019,34(3),419-428","journal-title":"J Bone Miner Res"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"Cosman F.","year":"2016","unstructured":"Cosman F.; Crittenden D.B.; Adachi J.D.; Binkley N.; Czerwinski E.; Ferrari S.; Hofbauer L.C.; Lau E.; Lewiecki E.M.; Miyauchi A.; Zerbini C.A.; Milmont C.E.; Chen L.; Maddox J.; Meisner P.D.; Libanati C.; Grauer A.; Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 2016,375(16),1532-1543","journal-title":"N Engl J Med"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jbmr.3427","volume":"33","author":"Cosman F.","year":"2018","unstructured":"Cosman F.; Crittenden D.B.; Ferrari S.; Khan A.; Lane N.E.; Lippuner K.; Matsumoto T.; Milmont C.E.; Libanati C.; Grauer A.; FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. J Bone Miner Res 2018,33(7),1219-1226","journal-title":"J Bone Miner Res"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"Langdahl B.L.","year":"2017","unstructured":"Langdahl B.L.; Libanati C.; Crittenden D.B.; Bolognese M.A.; Brown J.P.; Daizadeh N.S.; Dokoupilova E.; Engelke K.; Finkelstein J.S.; Genant H.K.; Goemaere S.; Hyldstrup L.; Jodar-Gimeno E.; Keaveny T.M.; Kendler D.; Lakatos P.; Maddox J.; Malouf J.; Massari F.E.; Molina J.F.; Ulla M.R.; Grauer A.; Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 2017,390(10102),1585-1594","journal-title":"Lancet"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"Saag K.G.","year":"2017","unstructured":"Saag K.G.; Petersen J.; Brandi M.L.; Karaplis A.C.; Lorentzon M.; Thomas T.; Maddox J.; Fan M.; Meisner P.D.; Grauer A.; Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017,377(15),1417-1427","journal-title":"N Engl J Med"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jbmr.2932","volume":"32","author":"Genant H.K.","year":"2017","unstructured":"Genant H.K.; Engelke K.; Bolognese M.A.; Mautalen C.; Brown J.P.; Recknor C.; Goemaere S.; Fuerst T.; Yang Y.C.; Grauer A.; Libanati C.; Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass. J Bone Miner Res 2017,32(1),181-187","journal-title":"J Bone Miner Res"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"16009","DOI":"10.1038\/boneres.2016.9","volume":"4","author":"Wu M.","year":"2016","unstructured":"Wu M.; Chen G.; Li Y.P.; TGF-\u03b2 and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease. Bone Res 2016,4,16009","journal-title":"Bone Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/nm.2793","volume":"18","author":"Xian L.","year":"2012","unstructured":"Xian L.; Wu X.; Pang L.; Lou M.; Rosen C.J.; Qiu T.; Crane J.; Frassica F.; Zhang L.; Rodriguez J.P.; Jia X.; Yakar S.; Shouhong X.; Efstratiadis A.; Wan M.; Cao X.; IGF-1 released from bone matrix stimulates osteoblastic differentiation of MSCs by activation of mTOR during bone remodeling. Nat Med 2012,18(7),1095-1101","journal-title":"Nat Med"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"5841","DOI":"10.3390\/ijms20235841","volume":"20","author":"Irelli A.","year":"2019","unstructured":"Irelli A.; Sirufo M.M.; Scipioni T.; De Pietro F.; Pancotti A.; Ginaldi L.; De Martinis M.; mTOR links tumor immunity and bone metabolism: what are the clinical implications? Int J Mol Sci 2019,20(23),5841","journal-title":"Int J Mol Sci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s12663-016-0988-1","volume":"17","author":"de Queiroz Fernandes J.","year":"2018","unstructured":"de Queiroz Fernandes J.; de Lima V.N.; Bonardi J.P.; Filho O.M.; Queiroz S.B.F.; Bone regeneration with recombinant human bone morphogenetic protein 2: a systematic review. J Maxillofac Oral Surg 2018,17(1),13-18","journal-title":"J Maxillofac Oral Surg"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jconrel.2015.07.022","volume":"215","author":"Oryan A.","year":"2015","unstructured":"Oryan A.; Kamali A.; Moshiri A.; Potential mechanisms and applications of statins on osteogenesis: Current modalities, conflicts and future directions. J Control Release 2015,215,12-24","journal-title":"J Control Release"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1007\/s10067-018-4322-9","volume":"37","author":"Ruaro B.","year":"2018","unstructured":"Ruaro B.; Casabella A.; Paolino S.; Pizzorni C.; Ghio M.; Seriolo C.; Molfetta L.; Odetti P.; Smith V.; Cutolo M.; Dickkopf-1 (Dkk-1) serum levels in systemic sclerosis and rheumatoid arthritis patients: correlation with the Trabecular Bone Score (TBS). Clin Rheumatol 2018,37(11),3057-3062","journal-title":"Clin Rheumatol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.cca.2018.03.010","volume":"481","author":"Wu M.","year":"2018","unstructured":"Wu M.; Chen M.; Ma Y.; Yang J.; Han R.; Yuan Y.; Hu X.; Wang M.; Zhang X.; Xu S.; Liu R.; Jiang G.; Xu J.; Shuai Z.; Zou Y.; Pan G.; Pan F.; Dickkopf-1 in ankylosing spondylitis: Review and meta-analysis. Clin Chim Acta 2018,481,177-183","journal-title":"Clin Chim Acta"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3727\/096504018X15443011011637","volume":"27","author":"Jin Y.","year":"2019","unstructured":"Jin Y.; Xu L.; Wu X.; Feng J.; Shu M.; Gu H.; Gao G.; Zhang J.; Dong B.; Chen X.; Synergistic efficacy of the demethylation agent decitabine in combination with the protease inhibitor bortezomib for treating multiple myeloma through the Wnt\/\u03b2catenin pathway. Oncol Res 2019,27(6),729-737","journal-title":"Oncol Res"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1021\/acs.bioconjchem.8b00660","volume":"29","author":"Wang M.","year":"2018","unstructured":"Wang M.; Park S.; Nam Y.; Nielsen J.; Low S.A.; Srinivasarao M.; Low P.S.; Bone-fracture-targeted dasatinib-oligoaspartic acid conjugate potently accelerates fracture repair. Bioconjug Chem 2018,29(11),3800-3809","journal-title":"Bioconjug Chem"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/jcp.21747","volume":"220","author":"Gaur T.","year":"2009","unstructured":"Gaur T.; Wixted J.J.; Hussain S.; O\u2019Connell S.L.; Morgan E.F.; Ayers D.C.; Komm B.S.; Bodine P.V.; Stein G.S.; Lian J.B.; Secreted frizzled related protein 1 is a target to improve fracture healing. J Cell Physiol 2009,220(1),174-181","journal-title":"J Cell Physiol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/ijerph15071373","volume":"15","author":"Schweiger J.U.","year":"2018","unstructured":"Schweiger J.U.; Schweiger U.; H\u00fcppe M.; Kahl K.G.; Greggersen W.; Jauch-Chara K.; Fassbinder E.; The use of antidepressive agents and bone mineral density in women: a meta-analysis. Int J Environ Res Public Health 2018,15(7),15","journal-title":"Int J Environ Res Public Health"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/nm.2098","volume":"16","author":"Yadav V.K.","year":"2010","unstructured":"Yadav V.K.; Balaji S.; Suresh P.S.; Liu X.S.; Lu X.; Li Z.; Guo X.E.; Mann J.J.; Balapure A.K.; Gershon M.D.; Medhamurthy R.; Vidal M.; Karsenty G.; Ducy P.; Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med 2010,16(3),308-312","journal-title":"Nat Med"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00198-014-2944-6","volume":"26","author":"Bone H.G.","year":"2015","unstructured":"Bone H.G.; Dempster D.W.; Eisman J.A.; Greenspan S.L.; McClung M.R.; Nakamura T.; Papapoulos S.; Shih W.J.; Rybak-Feiglin A.; Santora A.C.; Verbruggen N.; Leung A.T.; Lombardi A.; Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the long-term odanacatib fracture trial. Osteoporos Int 2015,26(2),699-712","journal-title":"Osteoporos Int"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11914-013-0184-x","volume":"12","author":"Antebi B.","year":"2014","unstructured":"Antebi B.; Pelled G.; Gazit D.; Stem cell therapy for osteoporosis. Curr Osteoporos Rep 2014,12(1),41-47","journal-title":"Curr Osteoporos Rep"},{"key":"ref=77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200111","volume":"13","author":"Kim G.","year":"2018","unstructured":"Kim G.; Park Y.S.; Lee Y.; Jin Y.M.; Choi D.H.; Ryu K.H.; Park Y.J.; Park K.D.; Jo I.; Tonsil-derived mesenchymal stem cell embedded in situ crosslinkable gelatin hydrogel therapy recovers postmenopausal osteoporosis through bone regeneration. Plos One 2018,13(7)","journal-title":"Plos One"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.mce.2016.11.018","volume":"456","author":"Yang Y.","year":"2017","unstructured":"Yang Y.; Fang S.; Small non-coding RNAs-based bone regulation and targeting therapeutic strategies. Mol Cell Endocrinol 2017,456,16-35","journal-title":"Mol Cell Endocrinol"},{"key":"ref=79","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20180453","volume":"38","author":"Feng Q.","year":"2018","unstructured":"Feng Q.; Zheng S.; Zheng J.; The emerging role of microRNAs in bone remodeling and its therapeutic implications for osteoporosis. Biosci Rep 2018,38(3)","journal-title":"Biosci Rep"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/nm.3791","volume":"21","author":"Liang C.","year":"2015","unstructured":"Liang C.; Guo B.; Wu H.; Shao N.; Li D.; Liu J.; Dang L.; Wang C.; Li H.; Li S.; Lau W.K.; Cao Y.; Yang Z.; Lu C.; He X.; Au D.W.; Pan X.; Zhang B.T.; Lu C.; Zhang H.; Yue K.; Qian A.; Shang P.; Xu J.; Xiao L.; Bian Z.; Tan W.; Liang Z.; He F.; Zhang L.; Lu A.; Zhang G.; Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. Nat Med 2015,21(3),288-294","journal-title":"Nat Med"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.actbio.2017.07.009","volume":"59","author":"Zhao R.","year":"2017","unstructured":"Zhao R.; Xie P.; Zhang K.; Tang Z.; Chen X.; Zhu X.; Fan Y.; Yang X.; Zhang X.; Selective effect of epigenetic regulation of osteoblastic cell function by HANPs has significant implication on defining design parameters for a potential therapeutic use of nanomaterials. Acta Biomater 2017,59,338-350","journal-title":"Acta Biomater"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/ijms19030763","volume":"19","author":"Tucker W.O.","year":"2018","unstructured":"Tucker W.O.; Kinghorn A.B.; Fraser L.A.; Cheung Y.W.; Tanner J.A.; Selection and characterization of a DNA aptamer specifically targeting human HECT ubiquitin ligase WWP1. Int J Mol Sci 2018,19(3),19","journal-title":"Int J Mol Sci"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.2147\/IJN.S112415","volume":"11","author":"Lee M.S.","year":"2016","unstructured":"Lee M.S.; Su C.M.; Yeh J.C.; Wu P.R.; Tsai T.Y.; Lou S.L.; Synthesis of composite magnetic nanoparticles Fe3O4 with alendronate for osteoporosis treatment. Int J Nanomedicine 2016,11,4583-4594","journal-title":"Int J Nanomedicine"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1080\/19390211.2017.1343889","volume":"15","author":"Abdelkarem H.M.","year":"2018","unstructured":"Abdelkarem H.M.; Fadda L.H.; El-Sayed E.M.; Radwan O.K.; Potential role of L-arginine and vitamin E against bone loss induced by nano-zinc oxide in rats. J Diet Suppl 2018,15(3),300-310","journal-title":"J Diet Suppl"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/nu11010063","volume":"11","author":"Moon N.","year":"2019","unstructured":"Moon N.; Effiong L.; Song L.; Gardner T.R.; Soung, DY Tart Cherry prevents bone loss through inhibition of RANKL in TNF-overexpressing mice. Nutrients 2019,11,63","journal-title":"Nutrients"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/9075318","volume":"5","author":"Chai L.J.","year":"2018","unstructured":"Chai L.J.; Zhang Y.; Zhang P.Y.; Bi Y.N.; Yuan X.M.; Li Y.H.; Wang Y.Y.; Song L.; Sun L.K.; Zhou K.; The antiosteoporosis effects of Zhuanggu Guanjie Pill in vitro and in vivo. BioMed Research Int 2018,5,1-11","journal-title":"BioMed Research Int"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1186\/s13063-018-2854-6","volume":"19","author":"Cho Y.","year":"2018","unstructured":"Cho Y.; Lee S.; Kim J.; Kang J.W.; Baek Y.H.; Seo B.K.; Lee J.D.; The efficacy and safety of herbal medicine BHH10 in postmenopausal women with osteoporosis: study protocol for a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial. Trials 2018,19(1),482","journal-title":"Trials"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40199-017-0167-z","volume":"25","author":"Tabatabaei-Malazy O.","year":"2017","unstructured":"Tabatabaei-Malazy O.; Salari P.; Khashayar P.; Larijani B.; New horizons in treatment of osteoporosis. Daru 2017,25(1),2","journal-title":"Daru"},{"key":"ref=89","first-page":"169","volume":"24","author":"Ciccarelli F.","year":"2016","unstructured":"Ciccarelli F.; De Martinis M.; Sirufo M.M.; Ginaldi L.; Psoriasis induced by anti-Tumor Necrosis Factor-alpha agents: a comprehensive review of the literature. Acta Dermatovenerol Croat 2016,24(3),169-174","journal-title":"Acta Dermatovenerol Croat"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40425-018-0417-8","volume":"6","author":"Moseley K.F.","year":"2018","unstructured":"Moseley K.F.; Naidoo J.; Bingham C.O.; Carducci M.A.; Forde P.M.; Gibney G.T.; Lipson E.J.; Shah A.A.; Sharfman W.H.; Cappelli L.C.; Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series. J Immunother Cancer 2018,6(1),104","journal-title":"J Immunother Cancer"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/173946","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/173946\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/173946","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T19:22:45Z","timestamp":1621538565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/173946\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,6]]},"references-count":90,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2020,11,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867326666190730113123","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}